FDA panel votes 8-6 to ease restrictions on peptide BPC-157 despite safety warnings

The vote

An FDA advisory committee voted 8 to 6, with one abstention, to recommend placing the synthetic peptide BPC-157 on the bulks list, a move that would allow specialized pharmacies to compound it and make it more accessible to the public. The vote concluded a two-day meeting during which the panel reviewed seven peptides, including TB-500 and Semax. The recommendation puts the panel at odds with career FDA scientists, who had presented hours of testimony urging against greater access.

The peptide and its hype

Peptides are short chains of amino acids that occur naturally in the body, but synthetic versions have become a fixture of the wellness industry, promoted by influencers and celebrities as tools for optimization. BPC-157, in particular, has gained a following despite lacking FDA approval. The substances can be purchased online from chemical suppliers labeled "for lab use," and they are widely discussed on social media. The Biden administration had previously restricted these peptides from compounding, citing the absence of human clinical trial data.

Safety concerns

FDA scientists warned the panel that the safety and efficacy of BPC-157 remain unproven in human trials. Panel member Elizabeth Rebello, a pharmacist and anesthesiologist, said she voted no "because of the lack of efficacy data" and "safety concerns." Fellow panelist Brian Lee also opposed the recommendation, stating, "I think this endorsement can be potentially harmful, and I cannot in good conscience vote yes." Those voting in favor cited reasons including "the greater good" and "medical freedom."

I voted no because of the lack of efficacy data and safety concerns.

I think this endorsement can be potentially harmful, and I cannot in good conscience vote yes.

Political accusations

Medical experts accused Health Secretary Robert F. Kennedy Jr of stacking the advisory committee with individuals who have strong ties to the peptide industry. Kennedy has publicly stated that he has used peptides to treat injuries. Peter Lurie, president of the Center for Science in the Public Interest and a former FDA official, urged the panel to reject the recommendation, arguing that easing restrictions would undermine the agency's scientific standards.

What comes next

The panel's vote is non-binding, and the FDA will now decide whether to follow the recommendation. The broader review of the remaining six peptides continues, and the agency faces pressure from both industry advocates and public health watchdogs. The outcome will shape the regulatory landscape for a class of substances that sits at the intersection of wellness culture, political influence, and unsettled science.